Efficacy of Bifidobacterium longum, B. infantis and Lactobacillus acidophilus probiotics to prevent gut dysbiosis in preterm infants of 28+0-32+6 weeks of gestation: a randomised, placebo-controlled, double-blind, multicentre trial : the PRIMAL Clinical Study protocol
Introduction: The healthy ‘eubiosis’ microbiome in infancy is regarded as the microbiome derived from term, vaginally delivered, antibiotic free, breastfed infants at 4-6 months. Dysbiosis is regarded as a deviation from a healthy state with reduced microbial diversity and deficient capacity to cont...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
November 21, 2019
|
| In: |
BMJ open
Year: 2019, Volume: 9, Issue: 11 |
| ISSN: | 2044-6055 |
| DOI: | 10.1136/bmjopen-2019-032617 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1136/bmjopen-2019-032617 Verlag, lizenzpflichtig, Volltext: https://bmjopen.bmj.com/content/9/11/e032617 
|
| Author Notes: | Janina Marißen, Annette Haiß, Claudius Meyer, Thea Van Rossum, Lisa Marie Bünte, David Frommhold, Christian Gille, Sybelle Goedicke-Fritz, Wolfgang Göpel, Hannes Hudalla, Julia Pagel, Sabine Pirr, Bastian Siller, Dorothee Viemann, Maren Vens, Inke König, Egbert Herting, Michael Zemlin, Stephan Gehring, Peer Bork, Philipp Henneke, Christoph Härtel, for the behalf for the PRIMAL consortium |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1693631997 | ||
| 003 | DE-627 | ||
| 005 | 20230427031649.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200331s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2019-032617 |2 doi | |
| 035 | |a (DE-627)1693631997 | ||
| 035 | |a (DE-599)KXP1693631997 | ||
| 035 | |a (OCoLC)1341311764 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Marißen, Janina |e VerfasserIn |0 (DE-588)1207353477 |0 (DE-627)1693631857 |4 aut | |
| 245 | 1 | 0 | |a Efficacy of Bifidobacterium longum, B. infantis and Lactobacillus acidophilus probiotics to prevent gut dysbiosis in preterm infants of 28+0-32+6 weeks of gestation |b a randomised, placebo-controlled, double-blind, multicentre trial : the PRIMAL Clinical Study protocol |c Janina Marißen, Annette Haiß, Claudius Meyer, Thea Van Rossum, Lisa Marie Bünte, David Frommhold, Christian Gille, Sybelle Goedicke-Fritz, Wolfgang Göpel, Hannes Hudalla, Julia Pagel, Sabine Pirr, Bastian Siller, Dorothee Viemann, Maren Vens, Inke König, Egbert Herting, Michael Zemlin, Stephan Gehring, Peer Bork, Philipp Henneke, Christoph Härtel, for the behalf for the PRIMAL consortium |
| 246 | 3 | 3 | |a Efficacy of Bifidobacterium longum, B. infantis and Lactobacillus acidophilus probiotics to prevent gut dysbiosis in preterm infants of 28 + 0 - 32 + 6 weeks of gestation |
| 264 | 1 | |c November 21, 2019 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 31.03.2020 | ||
| 520 | |a Introduction: The healthy ‘eubiosis’ microbiome in infancy is regarded as the microbiome derived from term, vaginally delivered, antibiotic free, breastfed infants at 4-6 months. Dysbiosis is regarded as a deviation from a healthy state with reduced microbial diversity and deficient capacity to control drug-resistant organisms. Preterm infants are highly sensitive to early gut dysbiosis. Latter has been associated with sepsis and necrotising enterocolitis, but may also contribute to long-term health problems. Probiotics hold promise to reduce the risk for adverse short-term outcomes but the evidence from clinical trials remains inconclusive and none has directly assessed the effects of probiotics on the microbiome at high resolution. | ||
| 700 | 1 | |a Hudalla, Hannes |d 1985- |e VerfasserIn |0 (DE-588)1053957645 |0 (DE-627)790859149 |0 (DE-576)40992072X |4 aut | |
| 700 | 1 | |a Bork, Peer |d 1963- |e VerfasserIn |0 (DE-588)122539117 |0 (DE-627)705944476 |0 (DE-576)293313946 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d London : BMJ Publishing Group, 2011 |g 9(2019,11) Artikel-Nummer e032617, 9 Seiten |h Online-Ressource |w (DE-627)654747075 |w (DE-600)2599832-8 |w (DE-576)339269340 |x 2044-6055 |7 nnas |a Efficacy of Bifidobacterium longum, B. infantis and Lactobacillus acidophilus probiotics to prevent gut dysbiosis in preterm infants of 28+0-32+6 weeks of gestation a randomised, placebo-controlled, double-blind, multicentre trial : the PRIMAL Clinical Study protocol |
| 773 | 1 | 8 | |g volume:9 |g year:2019 |g number:11 |g extent:9 |a Efficacy of Bifidobacterium longum, B. infantis and Lactobacillus acidophilus probiotics to prevent gut dysbiosis in preterm infants of 28+0-32+6 weeks of gestation a randomised, placebo-controlled, double-blind, multicentre trial : the PRIMAL Clinical Study protocol |
| 856 | 4 | 0 | |u https://doi.org/10.1136/bmjopen-2019-032617 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://bmjopen.bmj.com/content/9/11/e032617 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200331 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 122539117 |a Bork, Peer |m 122539117:Bork, Peer |d 140000 |e 140000PB122539117 |k 0/140000/ |p 20 | ||
| 998 | |g 1053957645 |a Hudalla, Hannes |m 1053957645:Hudalla, Hannes |d 910000 |d 910500 |e 910000PH1053957645 |e 910500PH1053957645 |k 0/910000/ |k 1/910000/910500/ |p 10 | ||
| 999 | |a KXP-PPN1693631997 |e 3616528909 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 31.03.2020"],"recId":"1693631997","name":{"displayForm":["Janina Marißen, Annette Haiß, Claudius Meyer, Thea Van Rossum, Lisa Marie Bünte, David Frommhold, Christian Gille, Sybelle Goedicke-Fritz, Wolfgang Göpel, Hannes Hudalla, Julia Pagel, Sabine Pirr, Bastian Siller, Dorothee Viemann, Maren Vens, Inke König, Egbert Herting, Michael Zemlin, Stephan Gehring, Peer Bork, Philipp Henneke, Christoph Härtel, for the behalf for the PRIMAL consortium"]},"physDesc":[{"extent":"9 S."}],"id":{"eki":["1693631997"],"doi":["10.1136/bmjopen-2019-032617"]},"origin":[{"dateIssuedDisp":"November 21, 2019","dateIssuedKey":"2019"}],"titleAlt":[{"title":"Efficacy of Bifidobacterium longum, B. infantis and Lactobacillus acidophilus probiotics to prevent gut dysbiosis in preterm infants of 28 + 0 - 32 + 6 weeks of gestation"}],"relHost":[{"title":[{"title":"BMJ open","title_sort":"BMJ open"}],"disp":"Efficacy of Bifidobacterium longum, B. infantis and Lactobacillus acidophilus probiotics to prevent gut dysbiosis in preterm infants of 28+0-32+6 weeks of gestation a randomised, placebo-controlled, double-blind, multicentre trial : the PRIMAL Clinical Study protocolBMJ open","language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"BMJ Publishing Group","dateIssuedDisp":"2011-","publisherPlace":"London","dateIssuedKey":"2011"}],"id":{"issn":["2044-6055"],"zdb":["2599832-8"],"eki":["654747075"]},"note":["Gesehen am 02.10.20"],"part":{"text":"9(2019,11) Artikel-Nummer e032617, 9 Seiten","extent":"9","year":"2019","volume":"9","issue":"11"},"recId":"654747075","type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["2011 -"]}],"person":[{"display":"Marißen, Janina","role":"aut","roleDisplay":"VerfasserIn","given":"Janina","family":"Marißen"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Hannes","display":"Hudalla, Hannes","family":"Hudalla"},{"family":"Bork","role":"aut","roleDisplay":"VerfasserIn","given":"Peer","display":"Bork, Peer"}],"language":["eng"],"title":[{"subtitle":"a randomised, placebo-controlled, double-blind, multicentre trial : the PRIMAL Clinical Study protocol","title_sort":"Efficacy of Bifidobacterium longum, B. infantis and Lactobacillus acidophilus probiotics to prevent gut dysbiosis in preterm infants of 28+0-32+6 weeks of gestation","title":"Efficacy of Bifidobacterium longum, B. infantis and Lactobacillus acidophilus probiotics to prevent gut dysbiosis in preterm infants of 28+0-32+6 weeks of gestation"}]} | ||
| SRT | |a MARISSENJAEFFICACYOF2120 | ||